Impact of Weight on the Efficacy, Time to Response, and Safety of Linaclotide in Adults With Chronic Idiopathic Constipation or Irritable Bowel Syndrome With Constipation: Post Hoc Descriptive Analysis by Body Mass Index.
出版信息
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 9):9-10.
Abstract
摘要
相似文献
1
Impact of Weight on the Efficacy, Time to Response, and Safety of Linaclotide in Adults With Chronic Idiopathic Constipation or Irritable Bowel Syndrome With Constipation: Post Hoc Descriptive Analysis by Body Mass Index.体重对利那洛肽治疗成人慢性特发性便秘或便秘型肠易激综合征的疗效、起效时间及安全性的影响：按体重指数进行的事后描述性分析
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 9):9-10.
2
Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population.便秘型肠易激综合征或慢性特发性便秘患者开始口服治疗后的医疗保健利用情况及护理费用：美国医疗保险人群的真实世界分析
Adv Ther. 2025 May;42(5):2500-2512. doi: 10.1007/s12325-025-03163-1. Epub 2025 Mar 28.
3
Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis.利那洛肽治疗慢性特发性便秘和便秘型肠易激综合征的安全性和耐受性：汇总的 3 期分析。
Expert Rev Gastroenterol Hepatol. 2019 Apr;13(4):397-406. doi: 10.1080/17474124.2019.1575203. Epub 2019 Feb 18.
4
Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.利那洛肽治疗便秘型肠易激综合征和慢性便秘患者的疗效：一项荟萃分析。
Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. doi: 10.1016/j.cgh.2013.04.032. Epub 2013 May 2.
5
Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.鸟苷酸环化酶 C 激动剂治疗便秘型肠易激综合征和慢性特发性便秘的疗效和耐受性：系统评价和荟萃分析。
Am J Gastroenterol. 2018 Mar;113(3):329-338. doi: 10.1038/ajg.2017.495. Epub 2018 Jan 30.
6
Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.利那洛肽：一种用于治疗便秘型肠易激综合征的新型化合物。
Expert Opin Pharmacother. 2013 Oct;14(15):2125-32. doi: 10.1517/14656566.2013.833605. Epub 2013 Sep 5.
7
Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.优化利那洛肽在便秘型肠易激综合征患者中的应用：专家共识报告
Adv Ther. 2017 Mar;34(3):587-598. doi: 10.1007/s12325-016-0473-8. Epub 2017 Jan 12.
8
Efficacy of Linaclotide in Functional Dyspepsia and Constipation-Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial.
J Gastroenterol Hepatol. 2025 May;40(5):1119-1127. doi: 10.1111/jgh.16925. Epub 2025 Mar 13.
9
Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.利那洛肽，一种治疗慢性特发性便秘和便秘型肠易激综合征的新型疗法。
Adv Ther. 2013 Mar;30(3):203-11. doi: 10.1007/s12325-013-0012-9. Epub 2013 Feb 20.
10
Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.利那洛肽治疗对便秘型肠易激综合征成人患者工作效率和活动障碍的影响：两项随机、双盲、安慰剂对照3期试验的结果
Am Health Drug Benefits. 2014 Aug;7(5):289-97.
本文引用的文献
1
Multiple obesity indices suggest a close relationship between obesity and constipation: evidence from NHANES.多项肥胖指标表明肥胖与便秘密切相关：来自 NHANES 的证据。
BMC Public Health. 2024 May 9;24(1):1273. doi: 10.1186/s12889-024-18647-y.
2
Prevalence of constipation in adults with obesity class II and III and associated factors.II级和III级肥胖成年患者便秘的患病率及相关因素
BMC Gastroenterol. 2021 May 12;21(1):217. doi: 10.1186/s12876-021-01806-5.
Zotero 插件